Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Item

http://www.wikidata.org/entity/Q28291395

Q28291395

about

Trastuzumab-containing regimens for metastatic breast cancer Major clinical research advances in gynecologic cancer in 2013 Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer Cardiac toxicity of trastuzumab in elderly patients with breast cancer Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab Managing breast cancer in younger women: challenges and solutions Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer Progress in adjuvant chemotherapy for breast cancer: an overview Identifying and targeting tumor-initiating cells in the treatment of breast cancer Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications Current treatment of early breast cancer: adjuvant and neoadjuvant therapy Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Neoadjuvant therapy in the treatment of breast cancer Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies Developmental therapeutics for inflammatory breast cancer: Biology and translational directions Twenty years of anti-HER2 therapy-associated cardiotoxicity Treatment of early-stage HER2+ breast cancer-an evolving field Cardiac risk in the treatment of breast cancer: assessment and management.Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Translating neoadjuvant therapy into survival benefits: one size does not fit all.Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Dual HER2 blockade: preclinical and clinical data Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Safety and efficacy evaluation of pertuzumab in patients with solid tumors Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.An update on cardio-oncology.Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.

P2860

Q24194019-0536A040-EC89-4897-B558-1C7821C893DA Q24562146-ED697F03-550A-40D1-9374-5D22917C24EF Q26740393-E172F13C-15B4-4FBB-8A46-C2ED87C750BD Q26741182-1C5A7D36-3D0E-4C55-8989-93B48385C16F Q26751249-84DA0D4B-9210-4275-94FE-29F8693E9E37 Q26752780-68ACA95B-B1A0-416E-81C4-A6FC82E63940 Q26764879-E955A44F-8F43-4813-964E-2DB31BAE62DB Q26771184-E21C41DD-5C53-428E-9D56-25E27DA32A54 Q26785612-14B06F6E-F5B0-4D7E-9C47-3A7144D54651 Q26798078-D229A8DC-1106-4811-8213-45BEFAC7290C Q26851827-1F21F01C-1B49-46B0-BBAD-EC05355CA4EB Q27001729-27B850EC-55BE-4AF5-80E0-04218377C6C9 Q27011658-1D318E84-2947-4263-A6EF-43938AC9D03C Q27025863-C2371B2C-679B-4023-B71E-2B0238F33F77 Q27694514-7AD35E52-DA40-443B-AF04-A99AEED01E70 Q28072897-5325153E-1067-44BB-88DC-94A50FB5BD59 Q28075322-B3543DFB-6499-45E7-89EA-2D04F7AC68E0 Q28079391-4E3FEC2B-EF9A-4A90-BB1C-88490ADE189E Q28081124-9389466C-D275-41BB-9B71-9D879ABC8D05 Q28081385-7518C4E5-290A-476D-B240-8DB60C6D3DBD Q28083123-48D7B379-89B7-4F55-8015-B9A5E8432AC1 Q28085062-01DAF53D-DEE5-4251-9A68-BA12574BE483 Q28267134-B7969983-0DCE-4078-A28B-DB88045003F0 Q30251738-9C82A0F1-26CD-4F59-A088-CF138CE781B7 Q30315973-7F870FC2-F9B2-49A7-925B-A9EE9C93F402 Q30857631-E783B43A-B599-4FED-8980-5FC2668D99CA Q30941327-6A72A80F-8F90-4979-90BA-AB8E4D570934 Q33364587-B442A73F-369E-4DED-82CE-0AFECE41B650 Q33433275-DD4CEC00-7EFB-4F6B-B49F-0C812571126D Q33680109-C2A9F3CB-9DD9-4FA0-8F2C-C7257D1E23AE Q33714388-5C6882CE-8891-43B7-A630-F0786B78563E Q33949465-3269C58B-1E01-47C0-A927-B2257CD662B3 Q34023704-8A5B8675-6685-4C18-902B-E212E1388D93 Q34051972-98BC8D4F-5CF5-43E0-817B-2450E4BE62FB Q34389275-02B1804E-9A38-4228-A119-ED39BB8DC5B1 Q34485373-3B987B16-BFDF-49F5-8971-F8B5F15BABD9 Q34499609-B3C52429-6231-4162-A3AF-BA47F9E748B8 Q34567451-28A50286-3100-43A9-B42E-5338C1B5C1C3 Q34650059-B999EFAA-D85D-4FD0-B53C-642008B36924 Q35345642-E1F0BBA4-1F9F-4587-B546-91095B3FFF0E

P2860

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Item

http://www.wikidata.org/entity/Q28291395

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue